Immuno-Oncology | Specialty

Dostarlimab Plus Chemotherapy Meets ORR End Point in Metastatic Nonsquamous NSCLC

October 5th 2022

The addition of dostarlimab to chemotherapy led to an improvement in objective response rate vs pembrolizumab plus chemotherapy in patients with newly diagnosed metastatic nonsquamous non–small cell lung cancer.

FDA Awards Fast Track Designation to Eftilagimod Alpha Plus Pembrolizumab in Frontline NSCLC

October 5th 2022

The FDA has granted a fast track designation to eftilagimod alpha for use in combination with pembrolizumab as a frontline treatment for patients with stage IIIB/IV non–small cell lung cancer.

Pembrolizumab Plus Chemotherapy Drives Durable PFS, OS Benefit in Squamous NSCLC

September 24th 2022

Pembrolizumab plus chemotherapy demonstrated sustained improvements in progression-free survival and overall survival vs placebo plus chemotherapy in patients with treatment-naïve, metastatic squamous non–small cell lung cancer regardless of PD-L1 expression level.

Dostarlimab Provides Survival Benefits in dMMR Endometrial Cancer and Other Solid Tumors

September 22nd 2022

Single-agent dostarlimab showcased durable antitumor activity in patients with mismatch repair–deficient endometrial cancer and other solid tumors, with landmark estimates at various time points underscoring stable progression-free survival benefits in responders.

Immunotherapy Drives First-line Systemic Treatment for Advanced HCC

September 19th 2022

Evidence-based decisions have leveraged the use of immunotherapy combination atezolizumab plus bevacizumab for patients who receive a diagnosis of hepatocellular carcinoma.

Relatlimab Plus Nivolumab Approved in Europe for Unresectable or Metastatic Melanoma with PD-L1 <1%

September 17th 2022

The European Commission has approved the fixed-dose combination of relatlimab plus nivolumab for use in the frontline treatment of select patients with advanced or metastatic melanoma and a PD-L1 expression of less than 1% on tumor cells.

Neoadjuvant Cemiplimab Elicits Encouraging Pathologic Complete Response in CSCC

September 12th 2022

Cemiplimab produced pathologic complete responses as a neoadjuvant treatment in more than half of patients with resectable, stage II to IV cutaneous squamous cell carcinoma.

Frontline Tislelizumab Demonstrates Noninferior OS Vs Sorafenib in Unresectable HCC

September 11th 2022

Tislelizumab monotherapy provided a clinically meaningful overall survival benefit that was noninferior to sorafenib and showcased a favorable toxicity profile when used as a frontline treatment for patients with unresectable hepatocellular carcinoma.

Pembrolizumab/Anlotinib Combo Has Efficacy in Refractory or Platinum-Resistant Recurrent High-Grade Serous Ovarian Cancer

September 8th 2022

Pembrolizumab monotherapy and in combination with anlotinib demonstrated encouraging efficacy and safety when administered to patients with refractory or platinum-resistant recurrent high-grade serous ovarian cancer.

Pre- and Co-administration of Nivolumab Proves Safe in Locally Advanced Cervical Cancer Treated With CCRT

September 7th 2022

The addition of the pre- and co-administration of nivolumab with concurrent chemoradiation appeared to be safe and feasible in patients with locally advanced cervical carcinoma, according to data from the phase 1 GOTIC-018 trial.

Sequential Combo of Regorafenib and Nivolumab Shows Manageable Safety in Sorafenib-Pretreated HCC

September 6th 2022

The sequential treatment of regorafenib followed by nivolumab was found to have an acceptable toxicity profile in patients with hepatocellular carcinoma who progressed on and tolerated first-line sorafenib, according to early data from the phase 1/2a GOING trial.

Sequential Treatment With Immunotherapy and Targeted Therapy Denotes OS Benefit in BRAF-Mutant Melanoma

September 6th 2022

Immunotherapy in the form of ipilimumab plus nivolumab followed by the targeted therapy combination encorafenib plus binimetinib elicited an overall survival benefit in patients with untreated BRAF-mutated metastatic melanoma, according to findings from the phase 2 SECOMBIT trial.

FDA Approves Durvalumab Plus Gemcitabine/Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancers

September 2nd 2022

The FDA has approved durvalumab (Imfinzi) in combination with gemcitabine and cisplatin in adult patients with locally advanced or metastatic biliary tract cancers.

Vopratelimab Plus Pimivalimab Fails to Meet Tumor Reduction End Point in Select Metastatic NSCLC

August 31st 2022

The addition of vopratelimab to pimivalimab did not elicit a significant mean percent change of baseline tumor size in all measurable lesions vs pimivalimab alone in patients with immunotherapy-naïve, metastatic non–small cell lung cancer who were positive for the TISvopra predictive biomarker.

Immunotherapy Continues to Shape Evolving Treatment Armamentarium of GI Cancers

August 30th 2022

Several inroads have been made in the realm of gastrointestinal cancers, with novel immunotherapy combinations representing a significant advance spanning several tumor types.

Talimogene Laherparepvec Plus Pembrolizumab Misses Mark in Advanced Melanoma

August 25th 2022

The addition of talimogene laherparepvec to pembrolizumab did not significantly improve progression-free survival or overall survival over pembrolizumab alone in patients with advanced melanoma.

Atezolizumab Plus Vemurafenib/Cobimetinib Produces Intracranial Activity in BRAF V600–Mutant Melanoma With CNS Metastases

August 24th 2022

The addition of atezolizumab to vemurafenib and cobimetinib produced promising intracranial activity in patients with BRAF V600–mutated advanced melanoma and central nervous system metastases.

Maintenance With Niraparib and Ipilimumab Demonstrates PFS Benefit in Pancreatic Cancer

August 23rd 2022

Niraparib plus ipilimumab maintenance therapy elicited encouraging progression-free survival results in patients with advanced pancreatic cancer who achieved a stable response to platinum-based chemotherapy.

Tislelizumab/Chemo Combo Takes Step Toward Chinese Approval for Unresectable ESCC

August 23rd 2022

The China National Medical Products Administration’s Center for Drug Evaluation has accepted for review a supplemental biologics application seeking the approval of tislelizumab plus chemotherapy in the first-line treatment of patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

Durvalumab Plus Tremelimumab Elicits Favorable PFS Rates in Advanced Sarcomas

August 23rd 2022

The combination of durvalumab and tremelimumab demonstrated positive progression-free survival and overall survival rates with expected toxicity data in patients with advanced or metastatic soft tissue and bone sarcomas.